Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer
Ako Gannichida, Yusuke Nakazawa, Akira Kageyama, Takashi Kawakubo, Department of Pharmacy, The Jikei University Hospital, Tokyo 105-8471, Japan
Hirofumi Utsumi, Kazuyoshi Kuwano, Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo 105-8461, Japan
Author contributions: Gannichida A drafted the article and collected the data; Nakazawa Y designed the research; Nakazawa Y and Kageyama A analyzed and interpreted the data; Utsumi H and Kuwano K provided clinical advice; Nakazawa Y, Kageyama A, Utsumi H, Kuwano K, and Kawakubo T contributed to the critical revision of the article for important intellectual content; Kawakubo T provided the final approval for this article.
Institutional review board statement: The study protocol was approved by the Ethics Committee of the Jikei University [No. 31-048 (9547)].
Informed consent statement: This study was a retrospective observational study conducted using the opt-out method. Informed consent for the study was not required because the analysis used anonymous clinical data obtained after each patient had agreed to treatment through written consent. For full disclosure, the details of the study were mentioned in the opt-out document in the Jikei University School of Medicine.
Conflict-of-interest statement: Kazuyoshi Kuwano received study support from Ono Pharmaceutical Co., Ltd., Astellas Pharma Inc., Kyorin Pharmaceutical Co., Ltd. and Nippon Boehringer Ingelheim Co., Ltd. These companies did not have a role in conducting this study. All authors have no financial relationships to disclose.
Data sharing statement: No additional data are available.
: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yusuke Nakazawa, MDS, Assistant Lecturer, Department of Pharmacy, The Jikei University Hospital, 3-19-18 Nishi Shimbashi, Minato-ku, Tokyo 105-8471, Japan. email@example.com
Received: February 5, 2022
Peer-review started: February 5, 2022
First decision: May 12, 2022
Revised: June 1, 2022
Accepted: June 21, 2022
Article in press: June 21, 2022
Published online: July 24, 2022